Alchemab Therapeutics
Develops antibody therapeutics using patient immune-response data to identify protective antibodies for hard-to-treat diseases.
Overview
Alchemab Therapeutics is a life sciences company focused on discovering and developing antibody-based therapeutics. Its work centers on analyzing immune responses to identify naturally protective antibodies that could inform treatments for serious diseases. The company targets pharmaceutical and healthcare markets seeking novel therapeutic candidates, with differentiation tied to its immune-data-driven discovery approach. It raised $34 million in a Series A round in July 2026, described as €29.3 million and the British Business Bank’s largest life sciences investment to date.
Funding History
Alchemab Therapeutics secures €29.3 million as British Business Bank makes its largest life sciences investment yet
Frequently Asked Questions
- How much funding does AI Funding track for Alchemab Therapeutics?
- AI Funding tracks $34M for Alchemab Therapeutics across 1 funding round in this database.
- Who are Alchemab Therapeutics's investors?
- Alchemab Therapeutics's investors include British Business Bank.
- What does Alchemab Therapeutics do?
- Alchemab Therapeutics is a life sciences company focused on discovering and developing antibody-based therapeutics. Its work centers on analyzing immune responses to identify naturally protective antibodies that could inform treatments for serious diseases. The company targets pharmaceutical and healthcare markets seeking novel therapeutic candidates, with differentiation tied to its immune-data-driven discovery approach. It raised $34 million in a Series A round in July 2026, described as €29.3 million and the British Business Bank’s largest life sciences investment to date.
- Where is Alchemab Therapeutics headquartered?
- Alchemab Therapeutics is headquartered in Cambridge, United Kingdom.
Investors
Related Insights
A data-driven analysis of AI funding across all 17 sectors — from Foundation Models to AI Healthcare — with sector totals, deal counts, top companies, and investment trends for 2026.
A comprehensive geographic analysis of AI venture funding in 2026. San Francisco dominates with $31.4B across 32 companies, but Europe is breaking out with $7.1B in Paris, London, Amsterdam, and Stockholm. We map every city, sector specialization, and emerging hub.
A comprehensive, data-driven analysis of AI venture funding in Q1 2026. $25.9 billion raised across 94 deals, with 14 mega-rounds capturing 79.8% of total capital. Europe breaks out with $6.65B, and billion-dollar seed rounds arrive for the first time.